Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.·2020·Cancer Cell
DOI 10.1016/j.ccell.2019.12.006

Cited by (477)

Items 301–400 of 477

  1. Assembly and disassembly of stress granules in kidney diseases
    Jinchai Zhu, Hua Su · 2025 · iScience
  2. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy
    Jun Zhu, Tiantian Wu, Qiong Lin · 2023 · Molecular Biology Reports
  3. Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
    Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang et al. · 2024 · Clinical Cancer Research
  4. The Hippo pathway as an antitumor target: time to focus on
    Olga A. Koroleva, Alexander V. Kurkin, Alexander Albertovich Shtil · 2024 · Expert Opinion on Investigational Drugs
  5. Targeting the stress support network regulated by autophagy and senescence for cancer treatment
    Jae‐Jin Kim, Yeonghyeon Lee, Kyeonghwan Roh, Mi-Sung Kim, Chanhee Kang · 2021 · Advances in cancer research
  6. Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex
    Kepeng Che, Ajaybabu V. Pobbati, Caleb Nathaniel Seavey, Yuriy Federov, Anton A. Komar, Ashley Burtscher, Shuang Ma, Brian P. Rubin · 2022 · PLoS ONE
  7. Precision Therapy for Mesothelioma: Feasibility and New Opportunities
    Sean Dulloo, Aleksandra Bzura, Dean Anthony Fennell · 2021 · Cancers
  8. Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer
    Anna J. Wiecek, Stephen J. Cutty, Daniel Kornai, Mario Parreno-Centeno, Lucie E. Gourmet, Guidantonio Malagoli Tagliazucchi, Daniel H. Jacobson, Ping Zhang, Lingyun Xiong, Gareth L. Bond et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  9. Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease
    Wei Xuan, Dandan Song, Jianhua Hou, Xiuping Meng · 2025 · Frontiers in Pharmacology
  10. Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer
    Carmelo Cerra, Madeleine R. C. Tancock, Niko Thio, Ada Koo, AnnRann Wong, Karla J. Cowley, Swati Varshney, Madelynne O. Willis, Kaylene J. Simpson, Australian Ovarian Cancer Study Group et al. · 2025 · Cell Death Discovery
  11. Pressure loading regulates the stemness of liver cancer stem cells via YAP/BMF signaling axis
    Di Ma, Rui Liang, Qing Luo, Guanbin Song · 2024 · Journal of Cellular Physiology
  12. Expression of YAP suppresses cell proliferation and elevates the sensitivity of chemotherapy in retinoblastoma cells through lipid-peroxidation induced ferroptosis
    Liting Zhong, Xuejiao Meng, Jingjing Huang, Wenwen Hao, Yajing Zuo · 2023 · Chinese Clinical Oncology
  13. Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells
    Frank Celeste, Scott Powers · 2024 · Cancers
  14. Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR - and KRAS -Mutant Lung Cancer
    Xiaoxiao Sun, Karl Kumbier, Savitha Gayathri, Veronica Steri, Lani F. Wu, Steven J. Altschuler · 2024 · Cancer Research Communications
  15. CTHRC1 promotes the progression of clear cell renal cell carcinoma via the PI3K/AKT/GSK3β signaling pathway
    Wei Xie, Zheng Fu, Thomas Skutella, Qing Yan Jiang, Ronggui Zhang, Yuanfeng Zhang · 2025 · Genes & Diseases
  16. Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
    Lisa J. Brunet, David Alexandre, Ji‐Young Lee, Ma del Mar Blanquer-Rosselló, David Bracquemond, Alexis A. Guernet, Houssein Chhouri, Mathilde Goupil, Zoulika Kherrouche, Arnaud Arabo et al. · 2025 · Nature Communications
  17. Discovery of repurposed ethacrynic acid and its derivatives as novel TEAD inhibitors
    Wei Chen, Yuqing Nan, Yiping Zhang, Weidong Han, Yawen Wang, Bing Liu, Yiping Li · 2025 · European Journal of Medicinal Chemistry
  18. Sleepyhead, deadly awakening: the dynamics of metastatic organotropism, tumor dormancy and therapeutic implications
    Soumyajit Sarkar, P.K. Suresh · 2025 · Frontiers in Oncology
  19. The sleeping threat: targeting cancer dormancy to transform metastasis therapy
    Julio A. Aguirre‐Ghiso, Jose Javier Bravo‐Cordero, Wenjun Guo, Gregoire S. Lauvau, María Soledad Sosa · 2026 · Nature reviews. Cancer
  20. Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay
    Nancy E. Sealover, Jacob M. Hughes, Patricia L. Theard, Deepan Chatterjee, Amanda J. Linke, Bridget A. Finniff, Brianna R. Daley, Robert E. Lewis, Robert L. Kortum · 2024 · STAR Protocols
  21. Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma
    Yang Tian, Reshmee Bhattacharya, Seungyeul Yoo, Feng Jiang, Eric Y. H. Park, Genesis Lara Granados, Yudao Shen, Kwang‐Su Park, H. Ümit Kanıskan, Jian Jun Jin et al. · 2025 · iScience
  22. Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Nathan T. Bain, Yang Wang, Surein Arulananda · 2022 · Frontiers in Oncology
  23. APIP regulated by YAP propels methionine cycle and metastasis in head and neck squamous cell carcinoma
    Jiayi Li, Ruijie Wang, Mingyu Li, Zhiyuan Zhang, Shufang Jin, Hailong Ma · 2024 · Cancer Letters
  24. Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism
    Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Azusa Tanimoto, Akihiro Nishiyama, Hiroaki Konishi, Akimitsu Takagi, Hiroyuki Takahashi, S. Tiong Ong, Seiji Yano · 2020 · The Journal of Medical Investigation
  25. The molecular crosstalk of the hippo cascade in breast cancer: A potential central susceptibility
    Sulfath Thottungal Parambil, Gisha Rose Antony, Ajeesh Babu Littleflower, Lakshmi Subhadradevi · 2024 · Biochimie
  26. Targeting Minimal Residual Disease
    Yu‐Ting Chou, Paul Allegakoen, Trever Grant Bivona · 2024 · Annual Review of Cancer Biology
  27. Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib
    Guangzhi Ma, Dongsheng Wang, Yunfu Deng, Weijia Huang, Yifan Zhai, Shi‐Yong Sun · 2025 · Cancer Letters
  28. Macrophage regulation of tumor cell dormancy and the dormant niche: an overview in solid tumors
    Hongxing Zhang, Yiyue Ding, Lihui Gu, Ai Guo, Wanli Duan, Xuejie Wang, Baogang Zhang · 2025 · Cancer and Metastasis Reviews
  29. Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
    Elliott Joseph Brea, Simon Baldacci, Neil J. Savage, Francesco Facchinetti, Conor Hinchey, Sachiv Chakravarti, Alexis Mottram, Kenneth H. Ngo, Ha V. Vo, Brittaney A. Leeper et al. · 2025 · Cancer Immunology Research
  30. Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?
    Prachi Ghoderao, Eliza P. Kwiatkowska-Borowczyk, Sanjay H. Sahare, Hanna Dams‐Kozlowska · 2025 · Pharmaceutics
  31. Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis
    Kinjal Gupta, Nicholas James Koelsch, Victoria L. Neely, Laura Graham, Harry D. Bear, Michael O. Idowu, Hisashi Harada, Masoud H. Manjili · 2025 · British Journal of Cancer
  32. Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies
    Montse Sanchez-Cespedes, William W. Lockwood, Kenichi Suda, Eric E. Gardner, Tetsuya Mitsudomi, Katerina Politi, Christian Rolfo, Triparna Sen, Martin L. Sos, Tuomas Tammela et al. · 2025 · JTO Clinical and Research Reports
  33. Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway
    Cheng Li, Shuzhen Shi, Long Li, Yafang Wang, Mingyue Yao, Chengcheng Yu, Chuwei Yu, Chengying Xie · 2026 · Cell Death and Disease
  34. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
    Jun Liao, Wenxiu Yao, Yan Yu, Anlin Li, Jie Huang, Xingya Li, Longhua Sun, Yongchang Zhang, Yongsheng Wang, Xiujuan Qu et al. · 2026 · Cancer Cell
  35. Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model
    Thijs J. Hagenbeek, Jason R. Zbieg, Russell Smith, Sayantanee Paul, Luca Gerosa, Consuelo Torrini, Alissa D. Guarnaccia, Christy C. Ong, Jennifer Arca Lacap, Miaoran Ning et al. · 2026 · Nature Communications
  36. Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines
    Mario Perez-Medina, José Sullivan López-González, Jesus J. Benito-Lopez, Santiago Ávila‐Ríos, Maribel Soto-Nava, Margarita Matías‐Florentino, Alfonso Méndez-Tenorio, Miriam Galicia-Velasco, Rodolfo Chavez-Dominguez, Sergio Enrique Meza-Toledo et al. · 2024 · Cancers
  37. AI-enabled cancer target prioritization with optimal profiles balancing novelty, confidence and commercial tractability
    Xi Long, Barbara Steurer, Chun Wai Wong, Ekaterina Kozlova, Vladimir Naumov, Frank W. Pun, Alex Aliper, Feng Ren, Alex A. Zhavoronkov · 2024 · Future Medicine AI
  38. Augmented Acyl-CoA Biosynthesis Promotes Resistance to TEAD Palmitoylation Site Inhibition
    Kayla Nutsch, Marissa N. Trujillo, Lirui Song, Michael A. Erb, Jian Jeffery Chen, James J. Galligan, Michael J. Bollong · 2025 · ACS Chemical Biology
  39. Therapeutic opportunities for cancers presented by natural and synthetic compounds targeting the Hippo signaling pathway
    Thanapon Charoenwongpaiboon, Chuti Laowtammathron, Chanchao Lorthongpanich · 2021 · ScienceAsia
  40. Hippo Signaling Pathway and Cancer: Molecular Regulation and Therapeutic Targets
    Fariba Dehghanian, Seyedeh Zahra Hosseini Imani, Amirhossein Naghsh Nilchi, Sheyda Khalilian · 2022 · Precision Medicine and Clinical OMICS
  41. Effect of Hyperbaric Oxygen and Inflammation on Human Gingival Mesenchymal Stem/Progenitor Cells
    Johannes Tölle, Andreas Koch, Kristina Schlicht, Dirk Finger, Wataru Kaehler, Marc P. Höppner, Christian Graetz, Christof Edmund Dörfer, Dominik Maria Schulte, Karim M. Fawzy El‐Sayed · 2023 · Cells
  42. A SNAI2/CTCF Interaction is Required for NOTCH1 Expression in Rhabdomyosarcoma
    Prethish Sreenivas, Long Wang, Meng Wang, Anil Kumar Challa, Paulomi S. Modi, Nicole Rae Hensch, Berkley E. Gryder, Hsien-Chao Chou, Xiang R. Zhao, Benjamin D. Sunkel et al. · 2023 · Molecular and Cellular Biology
  43. Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells
    Yohei Matsui, Tadaaki Yamada, Yuki Katayama, Soichi Hirai, Ryo Sawada, Yusuke Tachibana, Masaki Ishida, Hayato Kawachi, Ryota Nakamura, Naoya Nishioka et al. · 2024 · Cancer Science
  44. Mechanisms of Adaptive Resistance to Targeted Therapy in RET -Aberrant Cancers
    Sandra Ortiz‐Cuaran, Camille Léonce · 2025 · Clinical Cancer Research
  45. Targeting Cancer Drug-Tolerant Persister Cells in Minimal Residual Disease
    Wei Zhang, Sorayut Chattrakarn, Fuhui Chen, Haobin Chai, Mariana Maranga, Jingwei Zhang · 2025 · International Journal of Drug Discovery and Pharmacology
  46. Injectable thermosensitive hydrogel-encapsulated paclitaxel liposomes enriched with miR-455-3p antagomir for dormancy therapy of salivary adenoid cystic carcinoma
    Mao Li, Xu Zhang, Lin-han Zhang, Jiarong Wang, Hua‐yang Fan, Zhi-chao Dou, Xinhua Liang, Yaling Tang · 2025 · Journal of Materials Chemistry B
  47. Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer
    Silvia Steinbauer, James Cowles, MohammadA Sabbaghi, Marle Poppelaars, Azaz Hussain, Marina Wagesreither, Daniela Laimer-Gruber, József Tóvári, Gergely Szakács, Agnes Csiszar · 2025 · npj Breast Cancer
  48. Targeting yes-associated protein to overcome imatinib resistance in gastrointestinal stromal tumor drug-tolerant persister cells
    Takashi Yokouchi, Tsuyoshi Takahashi, Toshirou Nishida, Koji Tanaka, Yukinori Kurokawa, Kazuyoshi Yamamoto, Takuro Saito, Takaomi Hagi, Kota Momose, Kotaro Yamashita et al. · 2025 · Gastric Cancer
  49. Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer
    Claire Lin, Matthew James Hadfield, Amol Rathore, Maximilian P. Pinho-Schwermann, Shengliang Zhang, Shaolei Lu, Petra den Hollander, Sendurai A. Mani, Attila A. Seyhan, Ariana Santopietro et al. · 2025 · Cancer Treatment Reviews
  50. Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance
    Heerim Yeo, Sang-Yun Kim, Sang‐Min Park · 2025 · Archives of Pharmacal Research
  51. Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression
    Madhurima Ghosh, Chao Wu, Abhishek Kumar, Monique B. Nilsson, John Victor Heymach, Weina Zhao, Jiang Yu, Xin Liu, Na Ding, Shike Wang et al. · 2025 · Journal of Clinical Investigation
  52. The Multi-Faceted Landscape of TEAD Inhibition: a 2017–2025 Patent and Literature Review
    Violet Yijang Chen, Jianfei Wan, Xiao Ding, Feng Ren, Alex A. Zhavoronkov · 2026 · Bioorganic Chemistry
  53. DOK1 facilitates the advancement of ccRCC
    Wei Xie, Yuanfeng Zhang, Bian Shu, Zhechuan Zhang, Ronggui Zhang · 2024 · Journal of Cancer
  54. Inhibition of BRD4 sensitizes NSCLC cells to osimertinib by suppressing APT1 and promoting MST1 palmitoylation
    Shaoqiang Wang, Yingying Zheng, Zhenyu Zhang, Lijie Qiu, Wolong Zhou, Heng Zhang · 2025 · Cell Death Discovery
  55. Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer
    Nelson K.Y. Wong, Xin Dong, Yen‐Yi Lin, Hui Xue, Rebecca Wu, Dong Lin, Colin C. Collins, Yuzhuo Z. Wang · 2022 · Cells
  56. Multiplexed protein profiling reveals spatial subcellular signaling networks
    Shuangyi Cai, Thomas Hu, Mythreye Venkatesan, Mayar Allam, Frank Schneider, Suresh S. Ramalingam, Shi‐Yong Sun, Ahmet F. Coskun · 2022 · iScience
  57. Graph-Based Spatial Proximity of Super-Resolved Protein–Protein Interactions Predicts Cancer Drug Responses in Single Cells
    Nicholas Y. Zhang, Shuangyi Cai, Mingshuang Wang, Thomas Hu, Frank Schneider, Shiyong Sun, Ahmet F. Coskun · 2024 · Cellular and Molecular Bioengineering
  58. Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR -mutant NSCLC
    Sarah Figarol, Célia Delahaye, Rémi Gence, Raghda Asslan, Sandra Pagano, Claudine Tardy, Jacques Colinge, Jean-Philippe Villemin, Antonio Maraver, Irene Ferrer et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  59. Imaging of MAP kinase dynamics reveals endocytic regulation of pulsatile signalling and network re-wiring in response to targeted therapy in EGFR-mutant non-small cell lung cancer
    Alix Le Marois, Sasha Bailey, Steven Hooper, Sunil Kumar, Hugh Sparks, Yuriy Alexandrov, Deborah R. Caswell, Fabian Fröhlich, Karin Schlegelmilch, Karishma Valand et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  60. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model
    Xinqi Li, Yueze Liu, Feihan Zhou, Wenbo Guo, Guangyu Chen, Jinxin Tao, Jingmin Huang, Jiangdong Qiu, Hao Chen, Bo Xu Ren et al. · 2025 · Cancer Letters
  61. Discovery and characterization of sulfonamide derivatives as transcriptional enhanced associate domain (TEAD) inhibitors: a novel approach for targeting hepatocellular carcinoma
    Yang Lu, Jian Gao, Jun Mo, Qiuqiu Shi, Yu Guo, Haifeng Chen, Linjie Li, Jingyi Zhao, Jinxin Che, Jiankang Zhang et al. · 2025 · Bioorganic Chemistry
  62. CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC
    Muhammed Yusuf · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  63. circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis
    Qianfan Hu, Yajing Wang, Yuxian Qian, Zi Wang, Hui Wang, Qingyun Wang, Rutao Li, Yipeng Feng, Yijian Zhang, Hanlin Ding et al. · 2025 · Cell Reports
  64. Elevated CD36 drives lymph node metastasis of breast cancer by activating Hippo-YAP signaling-mediated anoikis resistance
    Zhijian Huang, Xiaoyan Zhang, Jiajia Huang, Xiaojun Liu, Minting Liang, Fengyu Yang, Tianxiao Gao, Jieye Huang, Gan Xia, Jizhao Cao et al. · 2025 · Communications Biology
  65. Cellular senescence in lung cancer immune microenvironment and senotherapeutic opportunities
    Zhaolin Xu, Fangfang Liu, Shanshan Huang, Qian Chu · 2026 · iScience
  66. Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches
    Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang · 2026 · iMetaMed
  67. Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance
    Kanishka Tiwary, Jose Javier Bravo‐Cordero · 2026 · Molecular Oncology
  68. Therapy-Driven Molecular Evolution of Bladder Cancer: Roles of Cellular Plasticity and Tumor Microenvironment
    Seung-Woo Baek, Seo-Young Yoon, Seon‐Kyu Kim, Sun-Hee Leem · 2026 · International Journal of Molecular Sciences
  69. The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)
    Kostas A. Papavassiliou, Athanasios G. Papavassiliou · 2022 · Cancers
  70. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells
    Maako Nakajima, Kentaro Tanaka, Yasuto Yoneshima, Sho Yamashita, Daisuke Shibahara, Eiji Iwama, Isamu Okamoto · 2023 · Biochemical and Biophysical Research Communications
  71. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
    Rafael Rosell, Carlos Pedraz‐Valdunciel, Anisha S Jain, Chandan Shivamallu, Andrés Aguilar · 2024 · Expert Opinion on Investigational Drugs
  72. The Potential Links between lncRNAs and Drug Tolerance in Lung Adenocarcinoma
    William J. H. Davis, Catherine J. Drummond, Sarah D. Diermeier, Glen Reid · 2024 · Genes
  73. Recent Progress in Targeting TEA Domain Proteins (TEADs)
    Debra L. Brennan, Yufan Liang, Scott N. Mlynarski, Bing‐Yan Zhu · 2024 · Medicinal chemistry reviews
  74. Safety of image guided research biopsies in patients with thoracic malignancies
    Steffan K. Soosman, Matthew P. Schenker, Emanuele Mazzola, Emma Voligny, Anna Smokovich, Camden Phillip Bay, Tom T. Nguyen, Kesi Michael, Pasi Antero Janne, Michael S. Rabin et al. · 2022 · Lung Cancer
  75. Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas
    Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda Su Hyun Ahn, Isabel Ruth Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi et al. · 2023 · Clinical Cancer Research
  76. Integrative identification by Hi-C revealed distinct advanced structural variations in Lung Adenocarcinoma tissue
    Li Zhang, Tingting Song, Menglin Yao, Ying Yang, Zhiqiang Liu, Weimin Li · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  77. Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling
    Rachel M. Nakagawa, Andrew R. Beardsley, Sophia Durney, Mary-Kate Hayward, Vishvak Subramanyam, Nathaniel P. Meyer, Harrison Wismer, Hani Goodarzi, Valerie Marie Weaver, Daniel Van de Mark et al. · 2025 · eLife
  78. Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis
    Lin Ma, Jing Zhang, Zi Dai, Pei Liao, Jieshan Guan, Zhijie Luo · 2025 · Frontiers in Immunology
  79. The role of yes‐associated protein in nasal inflammatory diseases
    Bing Zhong, Yu Zhao · 2025 · Eye & ENT Research
  80. Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer
    Demeter Túrós, Morgane Decollogny, Anna Moyseos, Astrid Chanfon, Myriam Siffert, Joanne Bousmar, Lou Romanens, Jean‐Christophe Tille, Olivier Trédan, Sana Intidhar Labidi‐Galy et al. · 2026 · Nature Communications
  81. Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation
    Kazutaka Hosoya, Hiroaki Ozasa, Hironori Yoshida, Hitomi Ajimizu, Takahiro Tsuji, Masatoshi Yamazoe, Tatsuya Ogimoto, Kentaro Hashimoto, Tomoko Yamamoto Funazo, Keiichiro Suminaga et al. · 2025 · Cancer Science
  82. Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
    Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto-Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Khani Farahani, Deepankar Chakroborty, Nikol Dibus et al. · 2025 · Molecular Oncology
  83. Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery
    Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang · 2026 · MedComm – Oncology
  84. EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators
    Naiara Perurena, Marina Watanabe, Amy E. Schade, William R. Brown, Elizabeth Y. Luo, Alycia Gardner, Alexandra Indeglia, Akiko Yoshinaga, Rhea Sahu, Yoona Yang et al. · 2026 · Cancer Research
  85. Yifei Sanjie pill combined with gefitinib reduces the progression of EGFR-TKIs-resistant non-small cell lung cancer via YAP/ANKRD1 axis
    Yi Yuan, Ruisheng Zhou, Zengjie Ye, Lunwei Yang, Tianqi Gao, Huilin Xu, Xi Tang, Dailin Wu, Jing Li, Zilong Lin et al. · 2026 · Phytomedicine
  86. Drug-tolerant persister cells: the deadly survivors in hematological malignancies
    Qianying Ma, Tingyong Cao, 周兰霞, Juan Cheng, Li Zhao · 2026 · Frontiers in Pharmacology
  87. SAMD4 represses VGLL4 mRNA to activate TEAD and promote cancer progression
    Junji Otani, Miki Nishio, Riko Tokita, Hiroki Hikasa, Makoto Nishimori, Shingo Dan, Isao Naguro, Hidenori Ichijo, Masanori Miyanishi, Takehiko Sasaki et al. · 2026 · Oncogene
  88. Mechanobiology of non-small cell lung cancer: bridging tumor mechanics and therapeutic strategies
    Ravi D. Joshi, Diptesh T Patil, Khushwant S. Yadav · 2026 · Molecular Biology Reports
  89. From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer
    Yangyang Zhou, Haigang Geng, Yi Xu, Yanggang Hong, Bo Mei, Huanglei Wu, Xuanxuan Jin, Mengfan Ye, Ying Wang, Zan Shen et al. · 2026 · Journal of Experimental & Clinical Cancer Research
  90. Decoding drug resistance and apoptosis in biliary tract cancers using 3D tumor models
    Gurpreet Singh Gill, Om Saswat Sahoo, Arnab Nayek, Sajib Kumar Sarkar, Kailash Chand Kurdia, Nidhi Bhardwaj, Chandan J. Das, Saurabh Galodha, Gitanjali Goyal, Subhradip Karmakar et al. · 2026 · Frontiers in Cell Death
  91. Epithelial–mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis
    Xuecong Wang, Cecilia Xi Zhang, Yi Zhao, Jianxing He, Jean Paul Thiery · 2026 · Cancer and Metastasis Reviews
  92. YAP/TAZ-mediated resistance to EGFR inhibitors
    Hirohito Yamaguchi, Ghina M. Taouk · 2023 · Elsevier eBooks
  93. Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes
    Pinky Sharma, Yale S. Michaels, Joel D. Pearson · 2025 · Biochemical Journal
  94. Crosstalk between YAP-TEAD and PPAR suppresses HIV-1 LTR transcription in vitro
    Chenliang Zhou, Xiaolian Liu, Hong He, Ziyao Wu, Yihe Liu, Huba khamis Rashid, Lin Li · 2025 · Biochemical Pharmacology
  95. Genomic hallmarks of cellular dormancy in cancer and therapeutic implications
    Maria Secrier, Anna J. Wiecek, Stephen J. Cutty, Daniel Kornai, Mario Parreno-Centeno, Lucie E. Gourmet, Guidantonio Malagoli Tagliazucchi, Daniel H. Jacobson, Ping Zhang, Lingyun Xiong et al. · 2021 · Research Square
  96. Vasko Popa a diez años de su muerte
    Juan Octavio Prenz · 2001 · Cuadernos hispanoamericanos
  97. Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies Emergence of Slowly Growing Drug-Tolerant Cancer Cells
    Frank Celeste, Scott Powers · 2022 · Research Square
  98. Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML
    Bogdan Ovidiu Popescu, Carlos E. Stahlhut, Theodore C. Tarver, Sydney Wishner, Bianca J. Lee, Cheryl A.C. Peretz, Cuyler Luck, Paul J. Phojanakong, Juan A. Cámara, Henry Hongo et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  99. Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations
    Marc Creixell, Scott D. Taylor, Jacqueline S. Gerritsen, Song Yi Bae, Mingxuan Jiang, Teresa Augustin, Michelle Loui, Carmen Boixo, Pau Creixell, Forest M. White et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  100. Persister cancer cells are characterized by H4K20me3 heterochromatin that defines a low inflammatory profile
    Valentina Ramponi, Laia Richart, Marta Kovatcheva, Camille Stephan‐Otto Attolini, Jordi Capellades, Alice E. Lord, Óscar Yanes, Gabriella Ficz, Manuel Serrano · 2024 · bioRxiv (Cold Spring Harbor Laboratory)